Marksans Pharma Reports Nearly 170% Rise in Q1 Net Profit on Strong Sales Growth
Marksans Pharma reported a strong Q1 FY27 performance with consolidated net profit rising approximately 170% year-on-year to around Rs 157-159 crore. Sales increased 35.6% to Rs 840.8 crore, driven by significant growth in the UK, Europe, US, North America, Australia, and New Zealand markets. EBITDA rose 112.8% year-on-year to Rs 213 crore, with margins improving to 25.3%. The company also reported a cash balance exceeding Rs 1,000 crore and completed acquisitions in Europe, focusing on geographic expansion and new product launches.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (74/100). Lens Score 38/100.
Outlets measured: economictimes, businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (70–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 12 Aug, 08:25 am. Other outlets followed.